A look through the window at the evolving KRAS landscape
It’s time for an important update on the KRAS landscape and emerging opportunities in this niche.
I’ve mentioned this a few times, but the real kicker is going to come from rational combinations in different settings. Those companies who figure these out will emerge a stronger player than their competitors who focus on monotherapy.
With this idea in mind it behooves us to be alert and aware of what’s going on in the broader landscape beyond selective KRAS inhibitors against certain mutants.
Here we discuss the latest findings from two such targets, each quite different and yet both could have important roles to play going forward…
To learn more from our oncology analysis and get a heads up on the latest insights and commentary, subscribers can log-in or you can click to gain access to BSB Premium Content.
I must confess that a preclinical session I wandered into back in 2008/9 after getting lost in the far corner of a conference centre included brief details on an experimental 4–1BB CAR-T cell construct was both unusual and intriguing at a time when monoclonals and TKIs were all the rage. Who would have guessed then, though, that the fledgling idea would go onto leading a revolution in a new type of therapeutic approach that is becoming more commonplace a decade later?
Learning from preclinical developments is therefore a great way to understand what we might see in the future, however weird and wacky it may appear at the time. While many new concepts may not see the cold light of day, they can contribute in some small way to incremental improvements. After all, scientists are always looking to refine, enhance, and improve on what we have through knowledge, so we shouldn’t really be surprised when intriguing new ideas eventually start filtering through. There’s always a better way to do drug a target or find a new target.
With this mood in mind, we have already highlighted several areas where knowledge and creative scientific thinking is starting to evolve into new compounds, with other ideas yet to be fleshed out.
Today, we offer a new thought leader interview in this genre, where a relatively young biotech are doing something completely different and thinking creatively outside the box.
Whether their novel ideas will lead to a future blockbuster is anyone’s guess – we can certainly applaud their thinking and endeavour in trying to push the boundaries of what’s possible in an endeavour to change things for the better…
To learn more from our latest thought leader interview, conference coverage and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.